Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The contract invites clinical centers to join a consortium focused on testing treatment strategies using anti-obesity medications (AOMs) for youth with obesity. The goal is to identify approaches that maximize therapeutic benefits while minimizing risks by supporting healthy growth, nutritional status, physical activity, mental well-being, and overall quality of life. Priority research areas include determining the optimal timing for starting AOM therapy, appropriate dosage and duration, and the intensity of complementary lifestyle interventions. The initiative aims to address key developmental, psychological, and physical factors to avoid potential lifelong dependence on medication. Participating centers will engage in independent or multicenter trials within a collaborative framework that emphasizes standardized protocols, consistent data collection methods, central laboratory use, and shared analyses. The consortium will also explore predictors of treatment response to tailor interventions more effectively. This effort, supported by the National Institutes of Health under the Department of Health and Human Services, is designed to inform best practices for managing pediatric obesity through AOM therapy integrated with lifestyle modifications, ensuring interventions are feasible for implementation in clinical settings.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
This Notice of Funding Opportunity (NOFO) invites applications from clinical centers to participate in a consortium to test anti-obesity medication (AOM) treatment strategies for youth with obesity that maximize benefits and minimize risks of AOM use. Such intervention strategies should support the promotion of healthy growth and development; adequate nutritional status/intake, healthy eating and physical activity behaviors; mental health and well-being (e.g., body image, self-esteem, mood, etc.), and quality of life and be feasible to implement in clinical care settings. Priority areas include testing strategies to determine optimal developmental stage for AOM initiation, rate and amount of weight loss, AOM class, dose, frequency, and duration, and content and intensity of adjunct lifestyle therapies that may be imperative to ensure normal psychological and physical development and to potentially avoid lifelong dependence on AOMs. Investigators should also evaluate potential predictors of response/ nonresponse to various treatment strategies under evaluation. The consortium may conduct independent or multicenter trials but will collaborate on the development of protocols, use of common measures and data elements, use of a central laboratory and standardized procedures to collect data and biospecimens, and data analyses and manuscripts.
